Relevant Articles About Research and Clinical Trials in Breast Cancer
Trusted insights straight to your inbox and get the latest updates from OncWeekly
KEY TAKEAWAYS The INDYGO trial aimed to provide patients with updated exploratory analyses on OS, PFS, and HRQOL. The study concluded that intraoperative PDT alongside surgical excision and standard adjuvant therapy improved outcomes. Despite optimal multimodal...
KEY TAKEAWAYS The study aimed to investigate the efficacy and safety of NAIT in patients with GEJC. Researchers noticed the efficacy of NAIT in resectable GEJC alongside an acceptable toxicity profile; further investigation is ongoing. In recent years, neoadjuvant...
KEY TAKEAWAYS The study aimed to compare populations with differing childbirth ages to assess breast cancer and childbearing age overlap. The study emphasized increased awareness for women to make informed choices about delayed childbearing and cancer prevention....
The NATALEE phase III trial aimed to evaluate iDFS benefit in stage II/III HR+/HER2− early BC patients by adding RIB to the adjuvant …
The PALLAS phase III trial aimed to evaluate HER2-low as a prognostic and predictive biomarker for palbociclib benefit in PALLAS trial participants. Despite …
The SERENA-2 and SERENA-3 phase II trials aimed to investigate the biological effects of three camizestrant dose levels in ER+ HER2- primary breast …
Background Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint inhibitors. We previously developed a computational framework, REAL-neo, for identification, …
Background Only a subset of patients with gastric cancer experience long-term benefits from immune checkpoint inhibitors (ICIs). Currently, there is a deficiency in precise predictive biomarkers for ICI efficacy. The aim of this study was to …
Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological …
Background Cancer-intrinsic type I interferon (IFN-I) production triggered by radiotherapy (RT) is mainly dependent on cytosolic double-stranded DNA (dsDNA)-mediated cGAS/STING signaling and increases cancer immunogenicity and enhances the antitumor immune response to increase therapeutic efficacy. However, …